



IDENIX

CORPORATE FACT SHEET

Idenix Pharmaceuticals, founded in May 1998, is engaged in the discovery, development and commercialization of innovative treatments for human infectious diseases. Building on the company's expertise in medicinal chemistry and clinical development, Idenix believes that it is poised to become a leader in the antiviral pharmaceuticals market.

Idenix is focused on discovering and developing agents that it believes will advance the treatment of hepatitis B, hepatitis C and HIV. The company is pursuing a disciplined business strategy that seeks to capitalize upon the expertise of the company's management team. While focused on bringing its late-stage drug candidates to market, Idenix also believes that maintaining a pipeline of drug candidates for large and growing markets is critical to its long-term growth and success. Idenix seeks to optimize the value of new drug candidates through efficient, rapid and market-driven clinical and commercial development programs.

SCIENTIFIC EXPERTISE

Recognized experts in anti-infective chemistry and biology lead the Idenix drug discovery team. Advanced research technologies, complemented by an extensive library of compounds, are designed to help in the discovery of multiple new agents for a range of antiviral targets and to develop robust synthetic processes suitable for large-scale manufacturing. Idenix's clinical development team is led by experts in antiviral clinical trials. This expertise supports Idenix's goals of bringing investigational drugs to the market quickly and efficiently, while addressing important unmet medical needs in each therapeutic area. Discovery chemistry and screening at Idenix's European laboratories in Montpellier, France and Cagliari, Italy are enhanced through collaborations with the University of Montpellier II, the Centre National De La Recherche Scientifique, and the University of Cagliari.

PARTNERSHIPS

Idenix is developing its hepatitis B and its hepatitis C clinical product candidates in collaboration with Novartis Pharma AG. The collaboration arrangement provides that, upon successful development and approval, Idenix and Novartis will co-promote licensed products in the United States, France, Germany, Italy, Spain and the United Kingdom. Novartis holds the exclusive license to commercialize licensed products in the rest of the world.

Idenix Pharmaceuticals is traded on Nasdaq: IDIX.

LEADERSHIP

Jean-Pierre Sommadossi, Ph.D. – Founder, Chief Executive Officer and Chairman

David A. Arkowitz – Chief Financial Officer and Treasurer

Nathaniel A. Brown, M.D. – Executive Vice President, Clinical Research and Chief Medical Officer

John F. Weidenbruch – Executive Vice President and General Counsel

Susan L. Koppy – Senior Vice President, Business and Corporate Development

Paul J. Fanning – Vice President, Human Resources

Guy Macdonald – Executive Vice President, Operations

David N. Standring, Ph.D. – Senior Vice President, Biology

BOARD OF DIRECTORS

Jean-Pierre Sommadossi, Ph.D. – Founder, Chief Executive Officer and Chairman, Idenix Pharmaceuticals, Inc.

Charles W. Cramb – Executive Vice President, Finance and Technology and Chief Financial Officer, Avon Products, Inc.

Thomas Ebeling – Chief Executive Officer, Novartis Pharma AG

Wayne T. Hockmeyer, Ph.D. – Chairman, MedImmune

Thomas R. Hodgson – Former Chief Operating Officer and President, Abbott Laboratories

Robert Pelzer – General Counsel, Novartis Pharma AG

Denise Pollard-Knight, Ph.D. – Head of Nomura Phase 4 Ventures, Nomura International plc

Pamela Thomas-Graham – Group President, Liz Claiborne Inc.

US HEADQUARTERS

Idenix Pharmaceuticals, Inc.
60 Hampshire Street
Cambridge, MA 02139
Phone: (617) 995-9800
Fax: (617) 995-9801

EUROPEAN HEADQUARTERS

Idenix Sarl – Cap Gamma
1682 Rue De La Valsiere
34189 Montpellier Cedex 4
France
Phone: +33 4 99 52 22 52
Fax: +33 4 99 52 22 50

FOR MORE INFORMATION

MEDIA:
Teri Dahlman (617-995-9905)
INVESTORS:
Amy Sullivan (617-995-9838)
www.Idenix.com